X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs TTK HEALTHCARE - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA TTK HEALTHCARE SUN PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 31.9 16.9 189.0% View Chart
P/BV x 2.7 1.6 163.0% View Chart
Dividend Yield % 0.5 0.9 50.2%  

Financials

 SUN PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
TTK HEALTHCARE
Mar-19
SUN PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs7011,215 57.7%   
Low Rs433610 71.0%   
Sales per share (Unadj.) Rs110.4444.4 24.8%  
Earnings per share (Unadj.) Rs11.017.2 63.6%  
Cash flow per share (Unadj.) Rs17.227.6 62.4%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.40.5 64.4%  
Book value per share (Unadj.) Rs158.8177.9 89.2%  
Shares outstanding (eoy) m2,399.2614.13 16,979.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.1 250.0%   
Avg P/E ratio x51.652.9 97.6%  
P/CF ratio (eoy) x32.933.0 99.6%  
Price / Book Value ratio x3.65.1 69.6%  
Dividend payout %18.229.0 62.8%   
Avg Mkt Cap Rs m1,360,02112,894 10,547.4%   
No. of employees `00017.82.3 769.4%   
Total wages/salary Rs m53,6711,307 4,106.4%   
Avg. sales/employee Rs Th14,890.92,715.7 548.3%   
Avg. wages/employee Rs Th3,017.1565.3 533.7%   
Avg. net profit/employee Rs Th1,480.6105.4 1,404.6%   
INCOME DATA
Net Sales Rs m264,8956,279 4,218.9%  
Other income Rs m8,38878 10,822.7%   
Total revenues Rs m273,2826,356 4,299.4%   
Gross profit Rs m56,081496 11,315.8%  
Depreciation Rs m14,998147 10,223.9%   
Interest Rs m5,17634 15,312.7%   
Profit before tax Rs m44,295393 11,282.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452149 5,676.2%   
Profit after tax Rs m26,338244 10,807.5%  
Gross profit margin %21.27.9 268.2%  
Effective tax rate %19.137.9 50.3%   
Net profit margin %9.93.9 256.2%  
BALANCE SHEET DATA
Current assets Rs m316,3592,717 11,642.8%   
Current liabilities Rs m198,6431,571 12,646.0%   
Net working cap to sales %44.418.3 243.4%  
Current ratio x1.61.7 92.1%  
Inventory Days Days9532 294.9%  
Debtors Days Days10847 230.8%  
Net fixed assets Rs m213,178991 21,511.4%   
Share capital Rs m2,399141 1,698.0%   
"Free" reserves Rs m378,6062,373 15,954.8%   
Net worth Rs m381,0062,514 15,153.5%   
Long term debt Rs m17,7213 521,202.9%   
Total assets Rs m643,0284,158 15,464.5%  
Interest coverage x9.612.6 75.8%   
Debt to equity ratio x00 3,439.5%  
Sales to assets ratio x0.41.5 27.3%   
Return on assets %4.96.7 73.4%  
Return on equity %6.99.7 71.3%  
Return on capital %10.016.9 59.2%  
Exports to sales %03.6 0.0%   
Imports to sales %00.5 0.0%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs mNA31 0.0%   
Fx inflow Rs m40,816225 18,124.5%   
Fx outflow Rs m30,14371 42,389.8%   
Net fx Rs m10,673154 6,926.5%   
CASH FLOW
From Operations Rs m39,072173 22,571.6%  
From Investments Rs m-33,70897 -34,930.7%  
From Financial Activity Rs m-15,393-307 5,009.0%  
Net Cashflow Rs m-7,359-38 19,520.2%  

Share Holding

Indian Promoters % 63.7 65.4 97.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 3.7 138.6%  
FIIs % 23.0 5.2 442.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 25.8 32.2%  
Shareholders   133,026 12,723 1,045.6%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

TTK HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - GSK PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS